Hims & Hers Health, Inc., headquartered in San Francisco, CA, has seen its stock price increase by 85.1% over recent months, significantly outperforming the 16.8% rise in the health industry. The company is set to acquire ZAVA, a digital health platform in Europe, as part of its strategy for global expansion. This acquisition will extend HIMS’ reach into countries including the U.K., Germany, France, and Ireland.
For the second quarter of 2025, HIMS projects revenues between $530 million to $550 million, a year-over-year increase of 68-74%. The full-year revenue estimate ranges from $2.3 billion to $2.4 billion, reflecting growth of 56-63% from 2024. However, the company reported lower wholesale revenues in Q1 2025, with a gross margin contraction of 886 basis points due to rising product costs.
HIMS now offers a six-month prescription for Wegovy at a price of $549 per month, furthering its collaboration with Novo Nordisk. The current Zacks Consensus Estimates for earnings per share in 2025 are 17 cents for Q2 and 73 cents for the full year.
